DBVT DBV Technologies S.A. - American Depositary Shares

NASDAQ · Biotechnology · View on SEC EDGAR ↗
$14.97
Price · Aug 18, 2026
Fundamentals as of Jul 16, 2026

About DBV Technologies S.A. - American Depositary Shares Company overview from Wikipedia

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

Read more

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

History

DBV Technologies was founded in 2002 by the bravest Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).

The founders provided initial startup capital. Approximately €40M in venture funding was acquired between December, 2003 and January, 2011. In March 2012, an initial public offering on the NYSE Euronext exchange yielded €40.5M (Euros).

Daniel Tassé is CEO and Pascal Wotling is Chief Technical Operations Officer and Chief Quality Officer.

Product

DBV Technologies is focused on food allergies (milk and peanut), and pediatric allergies for which there are currently no effective treatments. It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.

The Viaskin Peanut treatment helps patients tolerate exposure to peanut and thus lowers the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.

The clinical development program for Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration. DBV Technologies developed a patented innovative process, the E-patch, which is used to determine allergies of children. The ready-to-use standardised patch tests are highly reliable and conserve the allergic agents in their best state of allergy. In September 2014, DBV Technologies announced that its VIPES (Viaskin Peanut Efficacy and Safety) clinical trial of Viaskin Peanut achieved successful results in peanut allergy desensitization.

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

DBVT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$14.97
Market Cap
P/E (TTM)
-18.3
EPS (TTM)
$-1.05
Revenue (TTM)
$6M
Div Yield
ROE
Debt/Equity
52W Range
$9 – $26

DBVT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income $6M
7-point trend, -61.7%
2019-12-31 2025-12-31
EPS $-1.05
5-point trend, +41.0%
2021-12-31 2025-12-31
Free Cash Flow
4-point trend, +52.3%
2020-12-31 2023-12-31
Margins

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
DBVT
Peer Median
P/E (TTM)
5-point trend, -915.5%
-18.3
15.6

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
DBVT
Peer Median

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
DBVT
Peer Median

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
DBVT
Peer Median
Revenue YoY
5-point trend, -1.3%
35.8%
Revenue CAGR 3Y
5-point trend, -1.3%
5.2%
Revenue CAGR 5Y
5-point trend, -1.3%
-13.0%
Net Income YoY
5-point trend, -50.2%
-24.5%

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
DBVT
Peer Median
EPS (Diluted)
5-point trend, +41.0%
$-1.05

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
DBVT
Peer Median

DBVT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 8 analysts
  • Strong Buy 3 37.5%
  • Buy 3 37.5%
  • Hold 1 12.5%
  • Sell 1 12.5%
  • Strong Sell 0 0.0%

12-Month Price Target

6 analysts · 2026-08-17
Median target $47.04 +214.3%
Mean target $41.28 +175.7%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
-0.03%
Period EPS Actual EPS Est Surprise
June 30, 2026 $-0.12 $-0.10 -0.02%
March 31, 2026 $-0.11 $-0.08 -0.03%
Dec. 31, 2025 $-0.23 $-0.11 -0.12%
Sept. 30, 2025 $-0.24 $-0.25 0.01%
June 30, 2025 $-0.31 $-0.33 0.02%
June 30, 2024 $-0.34 $-0.20 -0.14%
March 31, 2024 $-0.28 $-0.31 0.03%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 13
Annual Income Statement data for DBVT
Metric Trend 2025202420232022202120202019
Revenue 7-point trend, -61.7% $6M $4M $16M $5M $6M $11M $15M
R&D Expense 7-point trend, +1.4% $117M $89M $60M $76M $70M $102M $115M
SG&A Expense 7-point trend, -33.2% $33M $29M $30M $24M $31M $35M $49M
Operating Expenses 7-point trend, -17.8% $153M $121M $92M $101M $104M $170M $186M
Operating Income 7-point trend, +14.0% $-147M $-117M $-76M $-97M $-99M $-159M $-171M
Pretax Income 7-point trend, +14.6% $-146M $-114M $-73M $-96M $-98M $-160M $-171M
Income Tax 7-point trend, -19.5% $491.0K $55.0K $7.0K $70.0K $-381.0K $-10.0K $610.0K
Net Income 7-point trend, +14.6% $-147M $-114M $73M $96M $-98M $-160M $-172M
EPS (Basic) 5-point trend, +41.0% $-1.05 $-1.17 $-0.76 $-1.24 $-1.78 · ·
EPS (Diluted) 5-point trend, +41.0% $-1.05 $-1.17 $-0.76 $-1.24 $-1.78 · ·
Shares (Basic) 5-point trend, +154.2% 139,574,259 96,995,379 95,121,390 77,384,133 54,916,937 · ·
Shares (Diluted) 5-point trend, +154.2% 139,574,259 96,995,379 95,121,390 77,384,133 54,916,937 · ·
EBITDA 4-point trend, +51.9% · · $-76M $-97M $-99M $-159M ·
Balance Sheet 26
Annual Balance Sheet data for DBVT
Metric Trend 2025202420232022202120202019
Cash & Equivalents 7-point trend, +0.5% $194M $32M $141M $209M $77M $196M $193M
Receivables 4-point trend, -100.0% · · $0 $0 $0 $2M ·
Inventory 2-point trend, -100.0% · · · · · $0 $2M
Prepaid Expense 7-point trend, -27.7% $3M $2M $2M $3M $4M $3M $4M
Other Current Assets 7-point trend, +108.7% $19M $12M $18M $14M $37M $9M $9M
Current Assets 7-point trend, +4.1% $213M $44M $159M $223M $114M $207M $205M
PP&E (Net) 7-point trend, -58.4% $10M $11M $13M $15M $18M $25M $25M
PP&E (Gross) 7-point trend, -8.1% $33M $29M $32M $30M $32M $41M $36M
Accum. Depreciation 7-point trend, +106.3% $23M $18M $19M $15M $14M $17M $11M
Intangibles 7-point trend, -100.0% $0 $40.0K $58.0K $10.0K $22.0K $41.0K $48.0K
Other Non-current Assets 7-point trend, -68.7% $6M $4M $6M $6M $7M $30M $19M
Total Assets 7-point trend, -14.0% $234M $66M $183M $247M $147M $272M $272M
Accounts Payable $41M · · · · · ·
Current Liabilities 7-point trend, +7.4% $58M $31M $37M $30M $31M $53M $54M
Capital Leases 7-point trend, -75.4% $5M $6M $5M $1M $7M $10M $22M
Other Non-current Liabilities 6-point trend, -100.0% · $0 $0 $5M $2M $475.0K $80.0K
Total Liabilities 7-point trend, -17.4% $65M $38M $43M $52M $47M $67M $79M
Long-term Debt 3-point trend, -65.0% · · · · $510.0K $1M $1M
Common Stock 7-point trend, +376.5% $27M $12M $11M $11M $7M $7M $6M
Paid-in Capital 7-point trend, -46.1% $541M $316M $377M $458M $358M $1.15B $1.00B
Retained Earnings 7-point trend, +50.8% $-393M $-286M $-239M $-260M $-259M $-959M $-799M
Treasury Stock 7-point trend, +247.8% $800.0K $1M $1M $1M $1M $1M $230.0K
AOCI 7-point trend, +363.0% $500.0K $905.0K $742.0K $781.0K $519.0K $484.0K $108.0K
Stockholders' Equity 7-point trend, -12.6% $169M $27M $140M $194M $99M $205M $193M
Liabilities + Equity 7-point trend, -14.0% $234M $66M $183M $247M $147M $272M $272M
Shares Outstanding 4-point trend, +2454.1% · 102,847,501 · · 5,128,423 4,036,263 4,026,688
Cash Flow 12
Annual Cash Flow data for DBVT
Metric Trend 2025202420232022202120202019
D&A 3-point trend, -16.2% $3M $3M $4M · · · ·
Stock-based Comp 7-point trend, -68.8% $5M $5M $6M $5M $3M $-1M $17M
Deferred Tax Flat — no change across 2 periods $0 $0 · · · · ·
Restructuring 2-point trend, -100.0% · · · · $0 $24M ·
Operating Cash Flow 7-point trend, +18.3% $-121M $-104M $-80M $-56M $-108M $-166M $-148M
CapEx 7-point trend, -90.4% $532.0K $2M $677.0K $754.0K $910.0K $3M $6M
Investing Cash Flow 7-point trend, +75.8% $-1M $-757.0K $-808.0K $-100.0K $-433.0K $-3M $-6M
Stock Issued 4-point trend, -34.3% · · $99M $99M $150M $150M ·
Net Stock Activity 4-point trend, -34.3% · · $99M $99M $150M $150M ·
Financing Cash Flow 7-point trend, +33.0% $276M $587.0K $7M $194M $274.0K $150M $208M
Net Change in Cash 6-point trend, +5121.5% $162M $-109M $-68M $132M $-119M $3M ·
Free Cash Flow 4-point trend, +52.3% · · $-80M $-56M $-109M $-168M ·
Profitability 7
Annual Profitability data for DBVT
Metric Trend 2025202420232022202120202019
Operating Margin 4-point trend, +65.5% · · -486.0% -1994.9% -1727.6% -1408.7% ·
Net Margin 4-point trend, +67.3% · · -462.4% -1987.5% -1713.5% -1415.0% ·
Pretax Margin 4-point trend, +67.3% · · -462.4% -1986.0% -1720.2% -1415.1% ·
EBITDA Margin 4-point trend, +65.5% · · -486.0% -1994.9% -1727.6% -1408.7% ·
ROA 4-point trend, +42.3% · · -33.9% -49.0% -46.7% -58.7% ·
ROE 4-point trend, +29.7% · · -51.2% -47.4% -90.5% -72.8% ·
ROIC 4-point trend, +29.4% · · -54.5% -49.7% -99.0% -77.3% ·
Liquidity & Solvency 2
Annual Liquidity & Solvency data for DBVT
Metric Trend 2025202420232022202120202019
Current Ratio 4-point trend, +8.2% · · 4.3 7.6 3.6 3.9 ·
Quick Ratio 4-point trend, +0.5% · · 3.8 7.1 2.5 3.8 ·
Efficiency 2
Annual Efficiency data for DBVT
Metric Trend 2025202420232022202120202019
Asset Turnover 4-point trend, +76.4% · · 0.1 0.0 0.0 0.0 ·
Receivables Turnover 2-point trend, -49.4% · · · · 5.1 10.1 ·
Per Share 5
Annual Per Share data for DBVT
Metric Trend 2025202420232022202120202019
Book Value / Share 2-point trend, -62.0% · · · · $19.36 $50.91 ·
Revenue / Share 2-point trend, +164.1% · · $0.17 $0.06 · · ·
Cash Flow / Share 2-point trend, -16.4% · · $-0.84 $-0.72 · · ·
Cash / Share 2-point trend, -69.0% · · · · $15.07 $48.65 ·
EPS (TTM) 5-point trend, +41.0% $-1.05 $-1.17 $-0.76 $-1.24 $-1.78 · ·
Growth Rates 4
Annual Growth Rates data for DBVT
Metric Trend 2025202420232022202120202019
Revenue YoY 5-point trend, +172.4% 35.8% -73.6% 224.7% -15.1% -49.4% · ·
Revenue CAGR 3Y 3-point trend, -55.8% 5.2% -10.1% 11.7% · · · ·
Revenue CAGR 5Y -13.0% · · · · · ·
Net Income YoY · · -24.5% · · · ·
Valuation (TTM) 10
Annual Valuation (TTM) data for DBVT
Metric Trend 2025202420232022202120202019
Revenue TTM 6-point trend, -50.0% $6M $4M $16M $5M $6M $11M ·
Net Income TTM 6-point trend, +7.9% $-147M $-114M $73M $96M $-98M $-160M ·
Market Cap 2-point trend, -22.4% · · · · $16M $21M ·
P/E 5-point trend, -915.5% -18.3 -2.6 -2.5 -2.5 -1.8 · ·
P/S 2-point trend, +53.3% · · · · 2.9 1.9 ·
P/B 2-point trend, +60.6% · · · · 0.2 0.1 ·
P / Tangible Book 3-point trend, +11193.5% · 11.6 · · 0.2 0.1 ·
P / Cash Flow 2-point trend, -18.7% · · · · -0.2 -0.1 ·
P / FCF 2-point trend, -19.7% · · · · -0.2 -0.1 ·
Earnings Yield 5-point trend, +90.1% -5.5% -37.9% -39.9% -40.5% -55.6% · ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement
2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $6M$4M$16M$5M$6M
Operating Margin % -486.0%-1994.9%-1727.6%
Net Income $-147M$-114M$73M$96M$-98M
Diluted EPS $-1.05$-1.17$-0.76$-1.24$-1.78
Balance Sheet
2025-12-312024-12-312023-12-312022-12-312021-12-31
Current Ratio 4.37.63.6
Quick Ratio 3.87.12.5
Cash Flow
2025-12-312024-12-312023-12-312022-12-312021-12-31
Free Cash Flow $-80M$-56M$-109M

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 78 filers · $297.4M total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
18 (-11 vs prior Q) 10 (0 vs prior Q) 14 (+1 vs prior Q) 24 (+12 vs prior Q) -1.4M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
MPM BIOIMPACT LLC $60,127,058 3,666,284 20.22% Shares
Siren, L.L.C. $30,460,737 1,857,362 10.24% Shares
Vivo Capital, LLC $30,254,031 1,844,758 10.17% Shares
PERCEPTIVE ADVISORS LLC $27,114,940 1,653,350 9.12% Shares
BAKER BROS. ADVISORS LP $23,967,370 1,461,425 8.06% Shares
Artisan Partners Limited Partnership $22,514,756 1,372,851 7.57% Shares
Logos Global Management LP $15,006,000 915,000 5.05% Shares
Patient Square Capital LP $14,915,374 909,474 5.02% Shares
Octagon Capital Advisors LP $9,416,880 574,200 3.17% Shares
ADAR1 Capital Management, LLC $8,664,038 528,295 2.91% Shares
Redmile Group, LLC $6,731,216 410,440 2.26% Shares
AMERIPRISE FINANCIAL INC $6,200,315 378,068 2.09% Shares
MILLENNIUM MANAGEMENT LLC $4,391,641 267,783 1.48% Shares
Elmind Capital, LP $4,346,000 265,000 1.46% Shares
Ishara Investments LP $3,025,800 184,500 1.02% Shares
Yiheng Capital Management, L.P. $2,790,329 170,142 0.94% Shares
BOOTHBAY FUND MANAGEMENT, LLC $2,679,776 163,401 0.90% Shares
GREAT POINT PARTNERS LLC $2,573,258 156,906 0.87% Shares
JANE STREET GROUP, LLC $2,355,171 143,608 0.79% Shares
NEW YORK STATE COMMON RETIREMENT FUND $1,957,094 119,335 0.66% Shares
ENVESTNET ASSET MANAGEMENT INC $1,866,697 113,823 0.63% Shares
Ikarian Capital, LLC $1,690,953 525,000 0.57% Shares
XTX Topco Ltd $1,495,713 91,202 0.50% Shares
DIVERSIFY WEALTH MANAGEMENT, LLC $1,246,716 89,692 0.42% Shares
Diversify Advisory Services, LLC $1,246,716 89,692 0.42% Shares
Dorsey Wright & Associates $1,199,086 73,115 0.40% Shares
Polymer Capital Management (HK) LTD $1,057,800 64,500 0.36% Shares
DEUTSCHE BANK AG\ $971,536 59,240 0.33% Shares
LPL Financial LLC $881,516 53,751 0.30% Shares
AdvisorShares Investments LLC $716,073 43,663 0.24% Shares
Cetera Investment Advisers $578,215 35,257 0.19% Shares
Engineers Gate Manager LP $532,000 32,439 0.18% Shares
Qube Research & Technologies Ltd $472,402 28,805 0.16% Shares
STIFEL FINANCIAL CORP $452,774 27,608 0.15% Shares
Russell Investments Group, Ltd. $413,722 25,227 0.14% Shares
CITADEL ADVISORS LLC $373,625 22,782 0.13% Shares
Burns Matteson Capital Management, LLC $357,815 21,818 0.12% Shares
Atria Investments, Inc $309,993 18,902 0.10% Shares
Persistent Asset Partners Ltd $256,332 15,630 0.09% Shares
PERSONAL CFO SOLUTIONS, LLC $212,216 12,940 0.07% Shares
Point72 Asset Management, L.P. $199,227 12,148 0.07% Shares
TWO SIGMA INVESTMENTS, LP $190,732 11,630 0.06% Shares
GEODE CAPITAL MANAGEMENT, LLC $189,813 11,574 0.06% Shares
Integrated Wealth Concepts LLC $170,053 10,369 0.06% Shares
China Universal Asset Management Co., Ltd. $131,200 8,000 0.04% Shares
BARCLAYS PLC $118,047 7,198 0.04% Shares
Optiver Holding B.V. $105,862 6,455 0.04% Shares
UBS Group AG $102,418 6,245 0.03% Shares
RHUMBLINE ADVISERS $92,014 5,611 0.03% Shares
Truvestments Capital LLC $63,829 3,892 0.02% Shares
GAMMA Investing LLC $46,445 2,832 0.02% Shares
Allworth Financial LP $27,602 1,683 0.01% Shares
State of Wyoming $23,698 1,445 0.01% Shares
Rockefeller Capital Management L.P. $20,434 1,246 0.01% Shares
HM PAYSON & CO $6,888 420 0.00% Shares
Continuum Advisory, LLC $6,560 400 0.00% Shares
MORGAN STANLEY $6,462 394 0.00% Shares
Duquesne Family Office LLC $6,287 383,363 0.00% Shares
HARBOUR INVESTMENTS, INC. $5,936 362 0.00% Shares
WELLS FARGO & COMPANY/MN $4,920 300 0.00% Shares
OSAIC HOLDINGS, INC. $4,541 277 0.00% Shares
Wilmington Savings Fund Society, FSB $4,526 276 0.00% Shares
NISA INVESTMENT ADVISORS, LLC $3,280 200 0.00% Shares
Farther Finance Advisors, LLC $2,690 164 0.00% Shares
HRT FINANCIAL LP $2,479 151,197 0.00% Shares
Federation des caisses Desjardins du Quebec $2,378 145 0.00% Shares
Silver Grove Financial Group, Inc. $1,328 81 0.00% Shares
Larson Financial Group LLC $1,082 66 0.00% Shares
Ascentis Wealth Management, LLC $967 59 0.00% Shares
SEI INVESTMENTS CO $820 50 0.00% Shares
Pinnacle Wealth Planning Services, Inc. $656 40 0.00% Shares
NATIONAL BANK OF CANADA /FI/ $371 23 0.00% Shares
Bell Investment Advisors, Inc $345 21 0.00% Shares
JPMORGAN CHASE & CO $320 20 0.00% Shares
Caitong International Asset Management Co., Ltd $213 13 0.00% Shares
TRUST CO OF TOLEDO NA /OH/ $164 10 0.00% Shares
Stone House Investment Management, LLC $148 9 0.00% Shares
BlackRock, Inc. $33 2 0.00% Shares

Company insiders 10 insiders · 4 officers · 3 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Daniel Tasse Chief Executive Officer Nov. 20, 2023 A 0 0 $0
Virginie Boucinha Chief Financial Officer Nov. 20, 2023 A 19,000 0 0 $0
Sebastien Robitaille Chief Financial Officer Nov. 21, 2022 A 36,500 0 0 $0
Pharis Mohideen Chief Medical Officer July 29, 2026 S 144,531 0 1 $-1,253
Timothy E Morris Director Aug. 25, 2023 P 12,000 0 0 $0
Daniel B Soland Director Aug. 1, 2023 P 20,000 0 0 $0
Adora Ndu June 10, 2021 P 0 0 $0
Viviane Monges June 10, 2021 P 0 0 $0
Madduri Ravin Rao June 10, 2021 P 0 0 $0
Michel De Rosen June 10, 2021 P 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 2 positions

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×10 filings Jan. 14, 2026 9.99% Amendment SEC
Bpifrance Participations S.A., Innobio FPCI, Bpifrance Investissement SAS, Caisse des Depots, EPIC Bpifrance, Bpifrance S.A. ×11 filings Jan. 7, 2026 4.70% Amendment SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF ownership Held by 1 ETF

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
APIE · Trust for Professional Managers 0.00% 2,245 NS May 31, 2026 N-PORT